Sandbox
The global pharmaceutical and biotechnology sector has witnessed a substantial resurgence in dealmaking activity in 2026, marked by a wave of multi-billion dollar acquisitions. Cash-rich pharmaceutical majors are aggressively deploying capital to acquire de-risked, late-stage pipelines to offset revenue losses from impending patent cliffs expected later this decade.
Leading the charge are industry giants AbbVie and Merck KGaA, whose recent moves demonstrate a strategic emphasis on immunology and specialized life science research tools.
AbbVie Secures Apogee Therapeutics for $10.9 Billion
In a major expansion of its immunology portfolio, AbbVie announced the completion of its $10.9 billion acquisition of Apogee Therapeutics. Apogee’s lead clinical candidate is a next-generation monoclonal antibody targeting inflammatory skin conditions, including moderate-to-severe atopic dermatitis.
With blockbuster drug Humira facing biosimilar competition, AbbVie’s acquisition is designed to anchor its long-term market dominance in global immunology therapeutics alongside its existing blockbusters Skyrizi and Rinvoq.
Merck KGaA Bids $11.3 Billion for Bio-Techne
Simultaneously, German science and technology conglomerate Merck KGaA launched a successful $11.3 billion acquisition of Bio-Techne Corporation. Bio-Techne is a global leader in high-quality proteins, antibodies, and diagnostic reagents.
This transaction significantly bolsters Merck KGaA’s Life Science division, expanding its capability to support biopharmaceutical developers worldwide with essential research tools, specialized assays, and raw materials required for biologics manufacturing.
replenishing Pipelines for a Low-Exclusivity Era
Industry analysts project that global biopharma M&A transactions will continue to accelerate throughout the second half of 2026. As corporate tax dynamics stabilize and patent cliffs loom, big pharma companies are increasingly favoring strategic, de-risked bolt-on acquisitions to protect their future market valuations.
